top of page

Frequently
Asked Questions (FAQ)

For patients

Aunt Bette's Homemade Pecan Pie
Make It
Rockin’ Rocky Road Ice Cream
Make It
Tom’s Heavenly Apple Strudel
Make It
Joe’s Divine Butter Tarts
Make It

Collapsible text is great for longer section titles and descriptions. It gives people access to all the info they need, while keeping your layout clean. Link your text to anything, or set your text box to expand on click. Write your text here...

  • What is the RadTox™ test and how does it work?
    RadTox™ is a liquid biopsy test that quantifies circulating cell-free DNA (cfDNA) levels in plasma to monitor cancer treatment response and prognosis, using proprietary isobDNA™ technology.
  • What are the main advantages of the RadTox™ test over other liquid biopsy tests of the same indications?
    Key advantages include pan-cancer applicability, earlier detection of treatment response than imaging, small sample requirement, cost-effectiveness, and rapid turnaround time.
  • How does the RadTox™ test complement imaging and other diagnostic tests?
    RadTox™ provides real-time insights into tumor dynamics and treatment response, often earlier than imaging, and complements imaging and tissue biopsies for comprehensive monitoring.
  • Is RadTox™ ready for clinical use and covered by insurance?
    Yes, RadTox™ is a CLIA-certified LDT, and is covered by Medicare and some private insurers starting January 2024.
  • For which cancer types is the RadTox™ test suitable?
    RadTox™ test is a pan-cancer test suitable for monitoring treatment responses and tumor recurrence across all solid tumor types and stages, without the need for prior tumor genomic profiling.
  • How frequently can the RadTox™ test be performed?
    RadTox™ can be performed as frequently as weekly or biweekly during active treatment, and monthly during surveillance, enabling continuous monitoring.
  • What is the turnaround time for RadTox™ test results?
    The RadTox™ test has a rapid turnaround time of approximately 5-7 days, facilitating timely clinical decision-making.
  • How does the RadTox test compare to ctDNA (circulating tumor DNA) tests?
    While ctDNA tests provide genomic insights, RadTox™ quantifies total cfDNA levels, offering a complementary perspective on tumor burden and treatment response.
  • Can the RadTox™ test predict treatment outcomes or prognosis?
    Yes, studies show that baseline cfDNA levels and changes during treatment can be prognostic for outcomes like overall survival and progression-free survival.
  • How sensitive is the RadTox™ test in detecting molecular residual disease or tumor recurrence?
    RadTox™ can detect significant increases in cfDNA levels that may indicate molecular residual disease (MRD) or tumor recurrence, often earlier than imaging or conventional biomarkers.
bars.png
If you haven't found the answer you're looking for or would prefer to speak with someone directly, our customer service team is here to assist you. Feel free to reach out to us by calling 800-246-8878 or emailing
radtox@diacarta.com
questions.png

Thanks for submitting!

bottom of page